US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S.
CVS, Cigna, and UnitedHealth inflated cancer and HIV drug prices, FTC says
Three major drug middlemen needlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion in revenue, The Federal Trade Commission (FTC) said in a report released today.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
Big 3 PBMs reaped $7.3B from generic specialty drug markups: FTC
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.
Top three insurers reaped $7.3 billion through their drug middlemen’s markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from ‘excess’ prescription price hikes of 1,000% or more.
FTC says ‘Big 3 PBMs’ marked up generic drugs by thousands of percent
The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which it says focuses on
PBMs Generated Billions in Drug Markups, FTC Says
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with, the FTC said in a new report.
PBMs made more than $7B marking up specialty generics: FTC
The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty generic drugs for cancer, HIV and other conditions, the Federal Trade Commission charged on Tuesday.
The Cigna Group's Fourth Quarter 2024 Earnings Release Details
Global health company The Cigna Group (NYSE:CI) will release its fourth quarter 2024 financial results on Thursday, January ...
Cigna Group stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
FTC Says CVS, Cigna and UnitedHealth Abuse Middleman Role
Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...
STAT1d
Cigna, Centene, Walgreens drop out of J.P. Morgan conference
Cigna and Centene were among a dozen companies that appeared on the initial JPM agenda that have bowed out of the conference.
Cigna Group stock underperforms Wednesday when compared to competitors
Cigna Group closed $91.51 below its 52-week high ($370.83), which the company achieved on September 16th.
Here's How Much $1000 Invested In Cigna 15 Years Ago Would Be Worth Today
Buying $1000 In CI: If an investor had bought $1000 of CI stock 15 years ago, it would be worth $7,625.07 today based on a ...
Cigna Healthcare Expands Access to Fertility and Family-Building Benefits and Services
Cigna Healthcare, the health benefits division of The Cigna Group (NYSE: CI), today announced a new offering in collaboration ...